A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
SurePath™ Pap and HPV mRNA E6/E7
Test Code15095
CPT Codes
87624, 88142<br><strong>This test is not available for California patient testing.</strong>
Includes
Pap results requiring physician interpretation will be performed at an additional charge (CPT code(s): 88141; HCPCS: G0124)
Preferred Specimen
Pap sample collected in 1 SurePath™ pap vial
Minimum Volume
1 SurePath pap vial
Instructions
For instructions refer to
//www.questdiagnostics.com/dms/Documents/Other/Specimen_Collection_and_Transport_Guide_2019.pdf
//www.questdiagnostics.com/dms/Documents/Other/Specimen_Collection_and_Transport_Guide_2019.pdf
Transport Container
1 SurePath pap vial
Transport Temperature
Room temperature
Specimen Stability
SurePath Pap
Room temperature: 28 days
Refrigerated: 90 days
Frozen: Unacceptable
SurePath HPV
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
SurePath Preservative in Aptima Transfer Tube
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Refer to local service area for specimen retention
Room temperature: 28 days
Refrigerated: 90 days
Frozen: Unacceptable
SurePath HPV
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
SurePath Preservative in Aptima Transfer Tube
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Refer to local service area for specimen retention
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
SurePath™ vials without the head of the collection device(s) in the fluid • Swabs • Cervical swabs in Digene® HC cervical sampler • Digene® vials
Methodology
Liquid Based-density Gradient Sedimentation • Transcription-Mediated Amplification (TMA)
Setup Schedule
Set up: Mon-Sat; Report available: 5 days
Reference Range
See Laboratory Report
Clinical Significance
Liquid-based Pap Testing is intended for use in the screening and detection of cervical cancer, pre-cancerous lesions, atypical cells and all other cytologic categories as defined by The Bethesda System for Reporting Results of Cervical Cytology. Pap screening is not reliable for the detection of endometrial cancer. HPV DNA testing in conjunction with a Pap test in women 30 years and older can be used adjunctively to assess the presence or absence of high-risk HPV types. This information, together with the physician's assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management. Detection of HPV using the hc2 High-Risk HPV DNA Test does not differentiate HPV types or infection with more than one type, and cannot evaluate persistence of any one type. The use of this test has not been evaluated for the management of women with prior cytologic or histologic abnormalities, hysterectomy, who are postmenopausal, or who have other risk factors (e.g., HIV+, immunocompromised, DES exposure, history of STD).
Gynecologic cytology is a screening test which is subject to both false positive and false negative results. For that reason, the test is most reliable when a satisfactory sample is obtained on a regular repetitive basis. Hence, these results must be interpreted in the context of historic and current clinical information.
Gynecologic cytology is a screening test which is subject to both false positive and false negative results. For that reason, the test is most reliable when a satisfactory sample is obtained on a regular repetitive basis. Hence, these results must be interpreted in the context of historic and current clinical information.
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153